Literature DB >> 10379743

The value of a second transurethral resection in evaluating patients with bladder tumors.

H W Herr1.   

Abstract

PURPOSE: The role of a routine second transurethral resection in evaluating and managing bladder tumors is defined.
MATERIALS AND METHODS: From January to October 1998, 150 patients with new or recurrent bladder tumors underwent repeat transurethral resection within 2 to 6 weeks after the initial resection, and the results, including the presence of residual tumor and tumor stage, were compared.
RESULTS: Of the 150 cases 36 (24%) had no and 114 (76%) had residual tumor on repeat transurethral resection. Of 96 cases with superficial (Ta, Tis, T1) bladder tumors 72 (75%) had residual noninvasive tumor and 28 (29%) were up staged to invasive tumor. Among 54 patients with a muscle invasive tumor 12 (22%) had no residual tumor on repeat transurethral resection. Results of the second resection changed tumor treatment in 50 patients (33%).
CONCLUSIONS: Many patients with bladder tumors have tumor present after an initial trans-urethral resection. Routine repeat resection is advised to control noninvasive tumors and to detect residual tumor invasion.

Entities:  

Mesh:

Year:  1999        PMID: 10379743     DOI: 10.1097/00005392-199907000-00018

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  76 in total

Review 1.  Current problems and needs in the treatment of pT1 G3 bladder carcinoma.

Authors:  Francisco Jose Martínez Portillo; Peter Alken
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  The value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications.

Authors:  S V Petrov; K A Malkhasyan; M Yu Ulyanin; E F Abdrakhmanov; R Sh Khasanov
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

4.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 5.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Choosing earlier therapy for muscle-invasive bladder cancer.

Authors:  John P Stein
Journal:  Rev Urol       Date:  2005

7.  Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system.

Authors:  Adam Kinnaird; Peter Dromparis; Howard Evans
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

Review 8.  Health care reform in 2010: transforming the delivery system to improve quality of care.

Authors:  Christopher P Filson; John M Hollingsworth; Ted A Skolarus; J Quentin Clemens; Brent K Hollenbeck
Journal:  World J Urol       Date:  2010-11-03       Impact factor: 4.226

9.  Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.

Authors:  Melih Balci; Altug Tuncel; Ozer Guzel; Yilmaz Aslan; Tezcan Sezgin; Ovunc Bilgin; Cagdas Senel; Ali Atan
Journal:  Int Urol Nephrol       Date:  2015-02-04       Impact factor: 2.370

10.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.